Last reviewed · How we verify
Misoprostol, modified-release pessary
Misoprostol is a prostaglandin E1 analogue that binds to prostaglandin receptors to increase uterine contractions and promote cervical ripening and dilation.
Misoprostol is a prostaglandin E1 analogue that binds to prostaglandin receptors to increase uterine contractions and promote cervical ripening and dilation. Used for Cervical ripening and labor induction in term pregnancy, Medical management of miscarriage or abortion.
At a glance
| Generic name | Misoprostol, modified-release pessary |
|---|---|
| Also known as | Misodel |
| Sponsor | Tampere University Hospital |
| Drug class | Prostaglandin analogue |
| Target | Prostaglandin E1 receptor (EP receptor) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Misoprostol acts as a synthetic prostaglandin that stimulates uterine smooth muscle contraction and softens the cervix by increasing local prostaglandin receptor signaling. The modified-release pessary formulation delivers the drug directly to the uterus over an extended period, allowing sustained local effects while minimizing systemic exposure. This mechanism facilitates labor induction and cervical preparation in obstetric settings.
Approved indications
- Cervical ripening and labor induction in term pregnancy
Common side effects
- Uterine hyperstimulation
- Abdominal pain
- Diarrhea
- Nausea
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: